Research & Development

A New Generation of Vaccines

Etubics is developing innovative immunotherapies and vaccines, utilizing our exclusive Adenovirus Vector Vaccines Platform (AVVP) technology and our patented human E.C7 human cell line, together the Etubics Platform. The Etubics Platform delivers a long lasting "active" immune response against a wide range of diseases. It has been proven to be safer, more efficient and more effective than current vectored vaccines and gene delivery platforms.

Etubics has recently completed early stage clinical trials with ETBX-011, an immunotherapy for late-stage metastatic colorectal cancer.  

Etubics is currently developing products to treat or protect against the following diseases:

Therapeutic Vaccines

 



Preventative Vaccines